Clinical News and Research

RSS

The Native Antigen Company expands infectious disease portfolio to include Sudan Ebolavirus Boniface 1976 Glycoprotein

...

From The Native Antigen Company 8 Dec 2022

New 3D organoid model reveals a possible biological target for treating GEJ cancers

Researchers at Johns Hopkins Medicine say they have created a laboratory-grown three-dimensional "organoid" model that is derived from human tissue and designed to advance understanding about how early stages of cancer develop at the gastroesophageal junction (GEJ) — the point where the digestive system's food tube meets the stomach.

2 Dec 2022

Specific genetic variant resulting in the early onset of epilepsy identified

Children’s Hospital of Philadelphia (CHOP) researchers have identified a particular genetic variant in SCN1A, the most common genetic epilepsy, that contributes to an earlier start of epilepsy with clinical features different from other epilepsies.

1 Dec 2022

Revealing the unappreciated role of POLQ in responding to DNA replication stress

Researchers at the Francis Crick Institute, in partnership with Artios, have discovered how an enzyme involved in DNA repair (POLQ) becomes critical to the survival of some tumors when the cancer cells lose the ability to employ a more frequent way of DNA repair.

1 Dec 2022

Using nanotechnology and magnetic manipulations to bioengineer 3D neural networks

Neurons are the fundamental units of the brain and nervous system, the cells responsible for receiving sensory input from the external world, for sending motor commands to our muscles, and for transforming and relaying the electrical signals at every step in between.

30 Nov 2022

Importance of localizing BRCA gene mutations for ovarian cancer treatment

Mutations in the BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 persons, respectively, elevate the risk of various malignancies such as ovarian, breast, pancreatic, and prostate cancer considerably.

30 Nov 2022

UC San Diego Alpha Clinic awarded $8 million to bring new stem cell-based therapies to patients

Stem cells show particular promise in treating diseases for which few other effective treatments exist.

25 Nov 2022

Applied Cells Inc. and GenScript enter strategic collaboration to deliver combined solutions for cell therapy development

November 18th, 2022. Today, Applied Cells Inc. and GenScript USA Incorporated announced their strategic collaboration to deliver combined cell isolation solutions for cell therapy drug development worldwide. Under this collaboration, GenScript will develop and supply its proprietary research and cGMP grade CytoSinct™ reagents for use in developing CAR-T and other Cell Therapy products on the Applied Cells MARS® Platform.

25 Nov 2022

Improving potential of cellular therapies with CAR T therapy

CAR T cells, or engineered immune cells, have demonstrated to the world the potential of customized immunotherapies to treat blood cancers. Researchers have just released highly encouraging preliminary data for CAR T therapy in a small group of lupus patients.

25 Nov 2022

Tankyrase protein plays an important role in helping drive bowel cancer

The inner workings of the main protein involved in an extensive range of cellular processes have been disclosed by researchers. This possibly sets the stage for improved and less toxic cancer drugs.

25 Nov 2022

Launch of stem cells into space to investigate stem cell aging

Lab tests on astronaut Scott Kelly’s blood cells after he returned from a year-long stay aboard the International Space Station (ISS) showed telomeric and pre-leukemic changes.

From UC San Diego 24 Nov 2022

The influence of genes and small molecules on personal disease risk

Each individual has a unique chemical fingerprint. Small molecules in the blood, like fats or sugars, have a significant impact on how the human body responds to stress, which diseases people are predisposed to, and how serious an illness will be.

23 Nov 2022

Chemically attenuated live DNA virus vaccine prevents viral infection

Rutgers researchers have devised a new way to prevent viral infections: a live-attenuated, replication-defective DNA virus vaccine that utilizes the substance centanamycin to create an altered virus for vaccine development.

From Rutgers University 22 Nov 2022

The Native Antigen Company introduces new range of influenza antigens

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest range of influenza antigens for the southern hemisphere’s 2023 flu season.

From The Native Antigen Company 21 Nov 2022

New guidelines for genomic consent benefit patients and researchers

How can Canada maximize the benefits of human genomic sequencing to deepen knowledge of disease? For researchers and decision-makers in this expanding field, new guidance published in CMAJ (Canadian Medical Association Journal) establishes the essential components for obtaining patient consent.

16 Nov 2022

NIH funds research on mRNA vaccines to stop cancer development

The National Cancer Institute at the National Institutes of Health has awarded a multidisciplinary team of Weill Cornell Medicine researchers a five-year $5.7 million grant to support a center dedicated to creating messenger RNA (mRNA) vaccines to prevent the development of cancer in at-risk groups.

15 Nov 2022